RSS

National Institute for Health and Care Excellence (NICE)

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Crysvita (burosumab) to be used in the treatment of X-linked hypophosphataemia (XLH) in children and young people with growing bones. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The National Institute for Health and Care Excellence (NICE) has published its positive guidance for the first selective interleukin (IL)-23 inhibitor to treat moderate to severe plaque psoriasis. more

News

A delegate of experts from the North of England will be showcasing their excellence in tackling antimicrobial resistance (AMR) to an international conference in Boston, Massachusetts, USA. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The National Institute for Health and Care Excellence (NICE) has issued its final appraisal determination (FAD) to Janssen recommending Tremfya (guselkumab) for treatment of adults with moderate to severe plaque psoriasis. more

News

The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented changes to the licence for valproate medicines — Epilim, Depakote and generics used to treat epilepsy and bipolar disorder — in the interest of public safety. more

News

Following a series of papers, published in The Lancet and featuring contributions from Professor Martin Underwood of Warwick Medical School, the NHS has published recommended changes to the treatment of low back pain. more

News

London-based scientists have found a new blood test that may be able to quickly predict if a female patient is responding to the breast cancer drug, palbociclib, earlier that is possible with currently available tests. more

Technology

A final appraisal determination (FAD) has been issued by the National Institute for Health and Care Excellence (NICE), recommending routine NHS use of avelumab for the treatment of adults in England, Wales and Northern Ireland with mMCC more

News

Breast cancer treatment, eribulin (Halaven), will still be accessible to patients with advanced metastatic breast cancer despite recent guidance by the National Institute of Health and Care Excellence (NICE), according to Eisai. more

News

Here we count down the top five tweets from @EPM_magazine that have gained the most impressions this week, taken from Twitter analytics. more

News

The National Institute for Health and Care Excellence (NICE) has issued a final appraisal decision (FAD) recommending the reimbursement of lenvatinib (Lenvima) for the treatment of differentiated thyroid cancer. more

News

The National Institute for Health and Care Excellence (NICE) has published a Final Appraisal Determination (FAD) recommending tivozanib as a first-line treatment option for advanced renal cell carcinoma (aRCC) in line with its licensed indication more

News

NHS England has revealed that thousands of patients have benefited from the new CDF and as a result of discounts it has secured on eight treatments, savings of around £140 million should be generated over the course of the next five years more

News

It has been announced by Eisai that the National Institute for Health and Care Excellence (NICE) has given a positive recommendation for the use of Kisplyx (lenvatinib) in combination with everolimus for the treatment of advanced renal cell carcinoma more

News

Two life-extending drugs will now be available to breast cancer patients on the NHS after price negotiations lead the National Institute for Health and Care Excellence (NICE) to approve them. more

News

Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. more

News

A new statement has been released based on a decision of the Board of the Association of the British Pharmaceutical Industry (ABPI) that it will not appeal the outcome of its judicial review application versus NICE more

News

Opdivo, also known as nivolumab, will now be available to NHS patients suffering from lung cancer as the drug’s manufacturer, Bristol-Myers Squibb, offers the National Institute for Health and Care Excellence (NICE) a new cancer drugs fund (CDF) deal more

News